New Delhi [India], May 20 (ANI): Amid the growing demand for vaccines in the country, Hyderabad-based Bharat Biotech has announced ramping up of additional manufacturing capacities for Covaxin at Chiron Behring Vaccines in Gujarat's Ankleshwar.
Covaxin production to be ramped up by 200 million doses
IANS / Updated: May 20, 2021, 22:56 IST
Hyderabad:
Covaxin by an additional 200 million.
The manufacturing capacities for India s first indigenous Covid vaccine have been ramped up at
Chiron Behring Vaccines, a wholly-owned subsidiary of Bharat Biotech at Ankleshwar, Gujarat.
The company plans to produce 200 million doses of Covaxin per annum in the
GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety, Hyderabad-based Bharat Biotech said in a statement.
The product availability at Ankleshwar is expected to commence from fourth quarter of 2021.
Covaxin Production To Be Scaled Up By Additional 200 Million Doses Covaxin Production To Be Scaled Up By Additional 200 Million Doses Bharat Biotech s announcement, which comes amid several states complaining of vaccine shortage, effectively takes the total volume of doses to nearly a billion per year, the vaccine maker said in a statement.
Bharat Biotech plans to produce additional 200 million doses of Covaxin per year.
New Delhi:
Bharat Biotech on Thursday said it s planning to ramp up the manufacturing capacity of its COVID-19 vaccine, Covaxin, by an additional 200 million doses per year. The announcement, which comes amid several states complaining of vaccine shortage, effectively takes the total volume of doses to nearly a billion per year, the vaccine maker said in a statement.
Bharat Biotech said on Thursday that production volumes have been ramped up by an additional 200 million doses at Ankleshwar, Gujarat. Product availability at Ankleshwar to commence from Q4 FY2022 (Jan-March). The company said the quick ramp up of additional manufacturing capacities for Covaxin was done at Chiron Behring Vaccines, Ankleshwar Gujarat, a wholly owned subsidiary of Bharat Biotech. The company plans to produce 200 million doses of Covaxin per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety, it said. Dear Reader,
Bharat Biotech big statement Covaxin production to reach 1 billion doses per year covid vaccine latest news indiatvnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatvnews.com Daily Mail and Mail on Sunday newspapers.